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. Differentiation of Treg cells in vivo by administration of aGalCer-liposomes encapsulated an antigen

ABSTRACT
We report here that the delivery of both α-galactosylceramide (αGalCer) 
Foxp3
+ T cells that produce both IL-10 and IFN-γ, and induced the antigen-specific suppression of the secondary antibody responses when boosted with OVA alone. These results indicate that antigen-containing αGalCer-liposomes can facilitate the development of tolerogenic antigenpresenting cells and inducible regulatory T cells that are involved in the suppression of immune responses to antigens.
INTRODUCTION
It is generally accepted that polarization of an immune response towards the Th2 type is an important prerequisite for the generation of antigen-specific IgE formation involved with atopic disorders (1) . Several approaches have been developed for the deviation of the T cell response to the Th1 type. Among these include chemical conjugation of CpG oligonucleotides (ODN) to antigen, which is a device to deliver CpG-ODN and antigen to the same antigen presenting cells. This proved to be a potent immunogen for priming Th1-biased immune response to the antigen (2) . Repeated injections of a CpGragweed antigen conjugate to antigen-primed mice prevented the secondary IgE antibody response to this allergen (3) . Clinical trials of this conjugate are in progress (4) .
An alternative approach for the suppression of the IgE antibody response is to induce immune tolerance via the development of antigen-specific regulatory T (Treg) 1 cells. It is well known that intravenous injection of denatured or modified antigen, which has lost the major B cell epitopes while maintaining the T cell epitope of the native antigen, into antigen-primed mice facilitates the differentiation of antigen-specific suppressor (regulatory) T cells (5, 6) . This effectively suppresses the secondary IgE antibody response to the native antigen. More recently it was shown that administration of antigen along with heat-killed listeria monocyotogenes (HKL) as an adjuvant reversed an established Th2 response and IgE antibody formation, and induced a Th1 type immune response to the antigen (7, 8) .
Further studies on the cellular mechanisms of the immune deviation revealed that immunization with HKL and antigen, included in incomplete Freund adjuvant, induced not only a conventional Th1 response, but also the differentiation of antigen-specific Treg cells that produced IL-10 and IFN-γ (7). The Treg cells were responsible for inhibition of allergen-induced airway hyper-reactivity and for suppression of the IgE antibody response (7) . A possible role of IL-10-producing Treg cells for the suppression of an IgE response is supported by the fact that transfer of OVA-specific Tr1 T cell clones concomitant with OVA immunization inhibited the primary IgE antibody response, whereas transfer of the same number of the antigen-specific Th1 clone failed to do so (8) .
In an experimental model of anterior chamberassociated immune deviation (ACAID), Sonoda et al (9, 10) have shown that NKT cells are required for the development of systemic immune tolerance. They provided evidence that the NKT cells expressed an invariant Vα14-Jα281 chain, and that the NKT cell-derived IL-10 played a critical role for the development of antigenspecific Treg cells and immune tolerance. These findings suggested the possibility that stimulation of NKT cells with a specific epitope, i.e., α-galactosylceramide (αGalCer), at the time of (or prior to) antigen-presentation to naïve T cells may facilitate the differentiation of Treg, rather than Th, cells specific for the antigen.
In the present studies, we prepared liposomes that contained αGalCer in a lipid bilayer with encapsulated OVA and examined their effect on antigen-induced immune responses. The results show that administration of the αGalCer-OVA-liposomes induces the development of antigen-specific Treg cells in vivo, and that the treatment of mice with these liposomes is effective for suppressing secondary antibody responses.
MATERIALS AND METHODS
Mice
BALB/c and (C57BL/6 X DBA/2) BDF1 mice were purchased from Charles River Japan, Inc. Vα14 NKT-deficient (Jα281-/-) mice were generated at Chiba University (11) and backcrossed for ten generations onto BALB/c background.
OVA-specific TCR transgenic DO11.10 mice were kindly provided by M. Kubo (RIKEN Research Center for Allergy and Immunology). All mice were maintained under pathogen-free conditions in our animal facility. The institutional committee for animal care and use in RIKEN approved all experimental procedures.
Reagents
α-galactosylceramide (αGalCer), KRN7000, was purchased from Kirin Brewery Co., Ltd., Japan. peptide were purchased from Sigma-Aldrich. Crystalline ovalbumin (OVA) was purchased from Seikagaku Co., Japan. 2,4-dinitrophenyl derivatives of OVA (DNP-OVA) and keyhole limpet hemocyanin (DNP-KLH) were purchased from Cosmo Bio, Japan.
Antibodies
For depletion of lineage-specific cells from spleens, biotinylated mAbs to CD3 (145-2C11), CD19 (1D3), CD49b (DX5), Ly-6G (Gr-1), TER-119 (BD Bioscience Pharmingen) and streptavidin-conjugated microbeads (Miltenyi Biotech) were used.
For flow cytometry, FITC-conjugated mAbs to IFN-γ ( XMG1.2 ), and CD4 (RM4-5), PE-conjugated mAbs to CD25 (PC61) and CD45RB (C363.16A), APCconjugated mAbs to IL-10 (JES5-16E3) and CD11c (HL3), biotinylated anti-CD4 (RM4-5) mAb and streptavidinconjugated PerCP Cy5.5 were purchased from BD Bioscience Pharmingen. Anti-CD16/32 (2.4G2; BD Bioscience Pharmingen) mAb was used for blocking the Fcγ receptor. PE-conjugated anti-Foxp3 mAb (FJK-16s) and staining kit were purchased from eBioscience.
For ELISA, biotinylated anti-mouse IgE (6HD5) was purchased from Seikagaku Co. Japan. Mouse IgE anti-DNP mAb H1 DNP-ε-26 and IgG1 anti-DNP mAb H1 DNP-γ-109 (12) was a gift from Dr. Fu-Tong Liu (University of California, Davis, CA). IgG2a anti-DNP mAb (MA-DNP-2) was purchased from Cosmo Bio, Japan. Horse radish peroxidase (HRP)-conjugated anti-IgG1 and IgG2a were purchased from Zymed.
Preparation of liposomes
Firstly, DC-Chol (0.83 mg), DOPC (0.77 mg), PEG-PE (0.029 mg), and α-GalCer (0.16 mg) were dissolved in chloroform and methanol (1:1). The dried films were suspended in 200 µl of PBS containing 400 µg/ml OVA, homogenized by sonication and mixed with 600 µl of dH 2 O. Uni-lamellar liposomes were prepared from multi-lamellar liposomes suspensions using a LiposoFast-Basic extruder (Avestin Inc.) by 25 cycles of manual extrusion through a 100 nm pore size polycarbonate membrane. Loss of α-GalCer and lipids trapped in the extruder was less than 10% of the starting material as estimated by the weight of lipids recovered.
OVAencapsulated αGalCer-liposomes were concentrated in an Amicon Ultra-4 centrifugal filter PL-100 (Millipore) and washed with PBS until no OVA protein was detectable in the flow through fraction. The concentrations of α-GalCer and OVA in the final liposome preparations were 200µg/ml and 50µg/ml, respectively. Liposome formulations were stored at 4 °C until use.
Ab measurement by ELISA
Serum anti-DNP IgG1 and IgG2a antibodies were measured as described (13) . Anti-DNP IgE Ab was measured with minor modifications. Briefly, microtiter plates (Corning) were coated overnight with 1 µg/ml rat anti-mouse IgE mAb (6HD5) at 4 °C. After blocking and washing, appropriate dilutions of serum samples or serial dilutions of anti-DNP IgE Ab as a standard were added. After incubation for 3 hr at 37 °C, plates were washed and 2.5 µg/ml biotinylated DNP-BSA (Cosmo Bio, Japan) in "Can Get Signal" immunoreaction enhancer solution (TOYOBO, Japan) was added to each well. The binding of biotinylated DNP-BSA was measured by HRP-conjugated streptavidin (Dako Cytomation) in "Can Get Signal" immunoreaction enhancer solution and TMB+ substrate system (Dako Cytomation).
Cell culture and culture medium
All cells were cultured in Click's medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum, 50 µM 2-mercaptoethanol, 10 mM Hepes (SigmaAldrich) and antibiotics. CD4 + naïve T cells were isolated from spleen cells of OVA-specific TCR transgenic DO11.10 mice by using CD4 + T cell isolation kit (Miltenyi Biotech). For the isolation of iNKT cells, dimeric rmCD1d:Ig was loaded with molar excess of αGalCer according to the instruction manuals of BD Biosciences for 16 h at 37 ° C. Spleen or lymph node cells were incubated with αGalCer-loaded rmCD1d:Ig dimer for 30 min at 4 °C. After washing, the cells were incubated with rat anti-mouse IgG1 microbeads for 30 min at 4 °C. iNKT cells were recovered by the binding to magnet.
Preparation of splenic DCs
DCs were prepared as previously described (14) . Briefly, spleens were swollen by infusion of 1 mg/ml collagenase D (Roche Molecular Biochemicals) in HBSS containing 10 mM Hepes buffer (pH 7), and incubated for 45 min at 37 °C. After cutting the spleen into small pieces, the cells were filtered through a 70 µm cell strainer (BD Bioscience), and suspended in 3 ml of 14.1% HistoDenz (Sigma-Aldrich). After the addition of 5 ml of X-VIVO 15 medium (BioWhittaker), the cell suspension was centrifuged at 1700 x g for 15 min and the low-density cell fraction was recovered. After incubation with a cocktail of biotinylated anti-CD3, CD19, CD49b, Ly-6G and TER119 mAbs at 4°C for 30 min, the cells were bound to streptavidin-conjugated microbeads. The enriched DCs were recovered from the flow-through fraction of a magnetic column (Miltenyi Biotech).
Flow cytometry
Cells were pre-treated with anti-CD16/CD32 mAb to prevent non-specific binding of Abs to cell Fc receptors. After washing with PBS containing 2% FCS and 0.09% sodium azide, the cells were incubated for 30 min at 4 °C with fluorescently-labeled mAbs. For staining of intracellular cytokines, cells were incubated with 50 ng/ml PMA and 500 ng/ml ionomycin for 4 h in the presence of 2 µM monensin (Protocol of BD Bioscience). Cells were fixed, and permeabilized by using Cytofix/Cytoperm in Perm/Wash buffer (BD Bioscience), and then incubated for 30 min at 4 °C with fluoro-labeled mAbs. Cytometric analysis and cell sorting were done using FACSCalibar, FACSVantage SE and FACSAria (BD Bioscience).
RT-PCR
Total RNA was isolated using RNeasy MinElute Cleanup kit (Qiagen).
For the amplification of glyceraldehyde-3-phosphate dehydrogenase (G3PDH), Foxp3 and IL-21, specific primers were synthesized as follows: 5'-accacagtccatgccatcac -3' (forward for G3PDH); 5'-tccaccaccctgttgctgta -3' (reverse for G3PDH); 5'-gccagtctggaatgggtgtccagg -3' (forward for Foxp3); 5'-ggtcgcatattgtggtacttgaag -3' (reverse for Foxp3); 5'-cccttgtctgtctggtagtcatc-3' (forward for IL-21) and 5'-atcacaggaagggcatttagc-3' (reverse for IL-21). RT-PCR was performed for 30 cycles at 57 °C for annealing.
Statistical analysis
The statistical significance of differences between the experimental groups was determined by nonparameric Mann-Whitney U test.
RESULTS
Suppression of T cell priming by pretreatment of mice with αGalCer-liposomes
In order to test possible effects of the liposomeformulation of αGalCer (αGC-liposomes) on the antibody response, either αGC-liposomes containing 2 µg αGalCer or αGC-OVA-liposomes containing 2 µg αGalCer and 0.5 µg OVA was injected intraperitoneally into groups of BDF1 mice 3 days prior to immunization with alumabsorbed DNP-OVA. Control groups received aqueous αGalCer or liposomes alone prior to immunization. As shown in Figure 1A , primary anti-DNP IgE, IgG1 and IgG2a antibody responses were completely suppressed by pretreatment with αGC-liposomes or αGC-OVAliposomes, but not by the pretreatment with aqueous αGalCer. Total serum immunoglobulin levels were not affected by either of the pre-treatments (data not shown). We wondered whether the lack of the antibody responses in the αGC-liposomes-treated mice was due to suppression of T cell priming. To test this possibility, we treated groups of BDF1 mice with an intraperitoneal injection of αGC-liposomes or aqueous αGalCer, and then immunized the mice with alum adsorbed DNP-OVA three days later. Splenic CD4 + T cells were obtained from each group of the mice 7 days after the immunization, and the cells were cultured for 48 hr with irradiated syngenic splenocytes in the presence of DNP-OVA of various concentrations. As shown in Figure 1B , the pretreatment with αGC-liposomes prevented IL-2 production and cell proliferation, whereas pretreatment with aqueous αGalCer rather enhanced them. It was also noted that antigen-nonspecific proliferation of CD4 + T cells induced by PMA/ionomycin was also substantially inhibited following αGC-liposome-treatment ( Figure 1B ). To elucidate the mechanism for the prevention of T cell priming, cytokine production of splenic CD4 + CD25
+ T cells from αGC-liposome-treated mice were analyzed 7, 10 and 14 days after the immunization with (n=5) received an intraperitoneal injection of αGC-liposomes or αGC-OVA-liposomes containing 2 µg α-GalCer, the same dose of aqueous αGalCer, or liposome alone. Three days later, they were immunized with alum-absorbed DNP-OVA (0.1 µg), and the concentration of anti-DNP Abs in their sera was determined by ELISA at day 14. ** p < 0.001 for αGC-liposome and αGC-OVA-liposome groups versus saline group. (B) Groups of BDF1 mice were pretreated with the same dose of aqueous αGalCer, αGC-liposomes, or saline, and then immunized with alum-adsorbed DNP-OVA 3 days later. Their splenic CD4 + T cells were obtained 7 days after the immunization, and aliquots (2 x 10 5 cells) of the cells were cultured with serial dilutions of DNP-OVA together with irradiated syngenic splenocytes (1 x 10 6 cells) or in the presence of 50 ng/ml PMA and 500 ng/ml ionomycin. After 48 h, IL-2 in the culture supernatants was assessed by ELISA. The cell proliferation was assessed by using the uptake of methylthiazole tetrazolium (MTT). Stimulation index represents the ratio of absorbance of samples versus that of a negative control. (C) Groups of BDF1 mice were pretreated with the same dose of αGC-liposomes or saline, and then immunized with alum-absorbed DNP-OVA three days later. Splenic CD4 + T cells were recovered from all mice despite the treatment with αGC-liposomes with different time periods after immunization (data not shown). Analysis for mRNA expression showed that IL-10, but neither IL-4 nor IFN-γ, mRNA expression was augmented on 7 and 14 days after immunization, but the expression level of Foxp3 mRNA of αGC-liposometreated mice was almost comparable with that of nontreated mice ( Figure 1C ). These results suggested that αGalCer in liposome formulation, but not in aqueous solution, could prevent both CD4 + helper T cell priming and the primary antibody responses initiated by the priming with alum-adsorbed antigen and IL-10-producing CD4 + CD25
+ T cells might be involved in these suppressive phenomena.
Antigen presenting cells in the regulation of IL-10 production by pretreatment with αGalCer-liposomes
We suspected that the opposite effects of αGC-liposomes versus aqueous αGalCer on the antigen-priming of naïve T cells might be due to the uptake of αGC-liposomes by non-DCs. To test this possibility, either aqueous αGalCer or αGC-liposomes was intraperitoneally injected into separate groups of BDF1 mice, and their spleens were obtained 24 hr after the injection. DCs were purified from the splenocytes by using the microbeads conjugated with anti-CD11c mAb. B cells and macrophages were then recovered successively from the residual cells using microbeads conjugated with anti-B220 mAb and anti-CD11b mAb, respectively. Aliquots of normal spleen cells as a source of iNKT cells were then cocultured with the purified DCs, B cells or macrophages from the αGalCer-treated mice or αGC-liposome-treated mice, and the concentrations of IFN-γ , IL-4 and IL-10 in the culture supernatants were determined. As shown in Figure 2A , DCs from the αGC-liposome-treated mice induced the higher production of cytokines than those from the aqueous αGalCer-treated mice. When B cells from the αGC-liposome-treated mice were co-cultured with normal spleen cells, IL-10 became detectable in the culture supernatant within 24 hr, and the concentration of the cytokine markedly increased by 48 hr. The concentration of IL-10 in the culture was much higher than that produced by the co-culture of the same spleen cells with DCs. Since the formation of IL-10 by the co-culture of the B cells with normal spleen cells was prevented by the addition of antiCD1d antibody, and culture supernatants of the B cells alone did not contain a detectable amount of IL-10 (results not shown), it appeared that presentation of CD1d-associated αGalCer on B cells to iNKT cells was responsible for the production of IL-10. In contrast, B cells of aqueous αGalCer-treated mice barely induced the formation of IL-10 ( Figure 2A ). These results suggested that the difference between B cells from the αGC-liposome-treated mice and those from the aqueous αGalCer-treated mice, with respect to the ability to induce IL-10 formation, was probably due to an enhancement of uptake of αGalCer in liposome formulation by B cells.
Since the splenic B cells comprise follicular and marginal zone B cells, we determined which subset is involved in the IL-10 formation. BDF1 spleen cells were obtained 24 hr after an intraperitoneal injection of αGC-liposomes. DCs in the splenocytes were depleted by using anti-CD11c-coupled microbeads.
The rest of the splenocytes were then fractionated by histodenz gradient, and B cells in both the high density (HD) and low density (LD) fractions were recovered by using anti-B220-coupled microbeads. The HD-B cells and LD-B cells were then cultured with normal spleen cells as the source of iNKT cells, and cytokines in the supernatants were determined. As shown in Figure 2B , only LD-B cells induced the formation of IL-10, whereas neither IL-4 nor IFN-γ was detected in the culture supernatant. Absence of both IL-4 and IFN-γ indicates that the formation of IL-10 in this system was not due to contamination of the B cell fraction with DCs. Moreover, LD-B cells were further fractionated into CD21
high CD23 -cell, CD21 middle CD23 high cell or CD21 low CD23 -cell fraction by flow cytometry. Each fraction was cultured with normal spleen cells, from which B cells had been depleted by using anti-B220-coupled microbeads. IL-10 production was detected in the culture supernatants of CD23-negative cell fractions at substantially higher amounts than in that of CD23-positive cell fraction ( Figure 2C ). To determine the cell source of IL-10 in this system, LD-B cells were obtained from the spleen of αGC-liposome-treated mice by the method described above, and the cells were cultured with normal spleen cells, from which B cells had been depleted. After 48 hr culture, supernatants were collected to confirm the presence of IL-10, and the cells were fractionated into B220 + cell and αGC/CD1d-Ig + cell fraction. Each cell fraction was analyzed for the presence of IL-10 mRNA by RT-PCR. As shown in Figure 2D , IL-10 mRNA was detected in B220 + B cell fraction more than in αGC/CD1d-Ig + cell fraction which contains iNKT cells. Taken together, the results suggested that presentation of αGalCer on CD23-negative LD-B cells to iNKT cells induced the formation of IL-10.
Expansion of CD11c
low CD45RB high cell population in vivo by the treatment of αGalCer-liposomes
Since αGC-liposomes are captured by LD-B cells in the spleen, when it was injected intraperitoneally (cf. Figure 2) , we determined as to whether the transfer of the LD-B cells pulsed with αGC-liposomes prior to the priming might induce the suppression of antibody responses. LD-B cells were obtained from the spleen of normal BDF1 mice, and incubated for 18 hr with αGC-liposomes. After washing, these cells or un-pulsed LD-B cells were transferred intravenously into normal BDF1 mice and then immunized with DNP-OVA in alum. As shown in Figure 3A , primary anti-DNP IgE, IgG1 and IgG2a antibody responses were completely suppressed by the transfer of αGC-liposome-pulsed LD-B cells, but not by that of LD-B cells alone. To clarify the suppression mechanism, we next analyzed splenic CD11c-positve cells three days after the transfer of αGC-liposome-pulsed LD-B cells. To enrich CD11c + DCs in the spleen cells, CD3, CD19, CD49b, Gr-1 or TER-119 marker positive cells were depleted by using the microbeads conjugated with specific mAbs. The results of flow cytometry of the DC-enriched fraction were shown in Figure 3B, low cells, while the expression of CD86 was comparable in the two populations ( Figure 3C ).
Upon stimulation with LPS, the CD11c low CD45RB
high population produced IL-10 but no IL-12, while the CD11c high CD45RB
low population secreted IL-12 but no IL-10 ( Figure 3D) (15) , and that this population expanded in vivo by the injection of αGC-liposomes, but not aqueous αGalCer. low DCs in their spleen were purified by cell sorting following the procedures described in the previous section (cf. Figure 3C ). Naïve CD4 + T cells were purified from the spleen cells of RAG2-/-DO11.10 mice, and the T cells were cultured either with the CD11c Their spleen cells were obtained 7 days after the last injection of the liposome, and the CD4 + T cells were recovered. Ten million CD4 + T cells from each group or normal CD4 + T cells were intravenously transferred into the BDF1 mice, which had been immunized with alum-absorbed DNP-OVA and boosted with DNP-OVA. As shown in Figure 5A , the CD4 + T cells from the αGC-OVA-liposome-treated mice significantly suppressed not only the IgE anti-DNP antibody response after the second boosting but also the ongoing antibody formations and the antibody responses of both IgG1 and IgG2a isotypes in the recipients, while the CD4 + T cells from the αGC-liposome-treated mice failed to do so.
Differentiation of Treg cells in vitro
The rest of the CD4 + T cells were cultured for 6 days with OVA-pulsed irradiated splenocytes, and were analyzed for intracellular Foxp3, IL-10 and IFN-γ. Most of CD4 + CD25 high cells from mice treated with αGC-liposomes expressed high level of Foxp3 but not IL-10 or IFN-γ (a in Figure 5B ). In contrast, the treatment with αGC-OVA-liposomes induced the development of
high cells, of which the majority expressed the low level of Foxp3 protein and both IL-10 and IFN-γ (b in Figure 5B ).
In the spleen of non-treated mice, CD4 + CD25 medium cells which expressed high level of Foxp3, but no cytokines, were only detected (c in Figure  5B ). The results suggested that CD4 + T cells producing both IL-10 and IFN-γ might represent inducible Treg cells generated by the treatment with αGC-OVA-liposomes.
4.6. Antigen-specific suppression by the treatment with αGC-OVA-liposomes BDF1 mice were immunized with alum-absorbed DNP-OVA and, after detection of the primary anti-DNP IgE antibody responses at 2 weeks, either αGC-liposomes or αGC-OVA-liposomes was injected intraperitoneally into the DNP-OVA-primed mice at day 21, 28 and 35. Seven days after the last injection of the liposomes, booster immunization of DNP-OVA was given to all groups, and the secondary anti-DNP-antibody response was assessed at 7 days after the booster. As shown in Figure 6 , anti-DNP antibody response of all Ig isotypes examined was markedly suppressed by the treatment with αGC-OVAliposomes. The treatment with αGC-liposomes slightly suppressed both the IgG1 and IgG2a antibody responses, but failed to affect the IgE antibody response. To determine the carrier-specific nature of the suppression by the treatment with αGC-OVA-liposomes, separate groups of BDF1 mice were immunized with alum-absorbed DNP-KLH; one group was treated by three intraperitoneal injections of αGC-OVA-liposomes, and another group was treated with αGC-liposomes. The results of the secondary antibody responses to DNP-KLH, given at 7 days after the liposome treatment, indicated that the treatment with αGC-liposomes slightly suppressed the secondary IgG1 and IgG2a antibody responses, but encapsulation of OVA in the liposomes did not enhance the suppressive effect. Neither αGC-liposomes nor αGC-OVA-liposomes suppressed the secondary IgE antibody response to DNP-KLH (Figure 6 ).
DISCUSSION
Data presented in this study clearly showed that pretreatment of BDF1 mice with αGC-liposomes suppressed the T cell priming, the primary antibody response to the antigen used for subsequent immunization, and the development of IL-10-producing CD4 + CD25 + T cells, while the pretreatment of the mice with the same dose of aqueous αGalCer rather enhanced the T cell priming (cf. Figure 1) . The difference between the effects of αGC-liposomes and those of aqueous  αGalCer on the immune response is probably ascribed to the difference in the antigen-presenting cells involved. It is well known that presentation of αGalCer by DCs to iNKT cells induces the production of large amounts of IFN-γ and IL-4 (17) , and that the production of IFN-γ by the NKT cells in this system requires the formation of IL-12 by the DCs (18, 19) . Since aqueous α-GalCer was presented by DCs, but not B cells (cf Figure 2A) , naïve CD4 + T cells were preferentially differentiated into helper T cells by virtue of cytokine productions from activated iNKT cells and DCs. As expected from previous reports on liposomes (20) , formulation of αGalCer in liposome appears to enhance the uptake of αGalCer by DCs, and resulted in an increase in the formation of the cytokines by iNKT cells (Figure 2A) . + T cells were cultured with irradiated syngenic splenocytes in the presence of 100 µg/ml OVA for 6 days, and were stained with biotinylated anti-CD4 mAb plus streptavidin-conjugated PerCP Cy5.5 and PEconjugated anti-CD25 mAbs. The cells were permeabilized, stained with PE-conjugated anti-Foxp3 mAb, or with FITCconjugated anti-IFN-γ and APC-conjugated anti-IL-10 mAbs, and then analyzed by flow cytometry. Expression of Foxp3 and cytokine production were analyzed in each of the squared cell populations.
However, the present experiments also showed that αGC-liposomes, injected intraperitoneally, was captured not only by splenic DCs but also by LD-B cells, and that the presentation of αGalCer by the B cells to iNKT cells resulted in the formation of IL-10 ( Figure 2B ). Since marginal zone B cells, which are included in the LD-B cell fraction, express high levels of CD1d and CD21 (21) , one may expect that αGalCer associated with CD1d molecules on the B cells will be presented to iNKT cells. Indeed, coculture of sub-cellular fractions in LD-B cells from the αGC-liposome-treated mice with normal spleen cells resulted in the formation of IL-10 mainly from CD21 high CD23
-cell and CD21 low CD23 -cell fractions, but not from CD21 middle CD23 high cell fraction which includes follicular B cells ( Figure 2C ). It is known that marginal zone B cells produce IL-10 upon bacterial stimulation (22) . The present experiments actually showed that IL-10 was derived from LD-B cells rather than iNKT cells, when LD B cells presented αGalCer to NKT cells ( Figure 2E ). In view of the finding by Colgan et al (23) that ligation of intestinal epitherial CD1d induced the formation of IL-10, we suspect that ligation of CD1d-associated αGalCer on the B cells by invariant Vα14 TCR induced the formation of IL-10 by the B cells.
It is well known that blood-borne particulate antigen is transported to marginal zone of the spleen, where DCs, marginal zone B cells and macrophages exist (24, 25) . Fujii et al. (26) have shown that intravenously injected αGalCer was captured by splenic DCs within 1 to 4 hrs after the injection, and that adoptive transfer of the splenic DCs into naïve mice induced selective activation of iNKT cells and maturation of DCs in the recipients. However, pretreatment of the recipient mice with aqueous αGalCer prior to the adoptive transfer of the αGalCer-pulsed DCs rendered iNKT cells unresponsive to the DCs, suggesting that presentation of αGalCer to iNKT cells by non-DCs inhibited the response of IFN-γ producing iNKT cells to αGalCer-bearing DCs (27) . Direct evidence for the hypothesis was obtained by using DC-depleted mice. Bezbradica et al (28) demonstrated that B cell-iNKT cell interactions in vivo appear to suppress DC-mediated αGalCer-induced activation of NKT cells and DC maturation. We suspect that immunoregulatory effects of αGC-liposomes are due to uptake of the liposomes by (Figure 2A) . Absence of IFN-γ and IL-4 in the culture supernatant of LD-B cells suggests that iNKT cells were not activated in the culture, probably due to failure of marginal zone B cells to produce IL-12. We speculate that early release of IL-10 in the marginal zone may affect maturation of DCs in the environment. Such cellular mechanisms of immune suppression by αGC-liposomes may be shared by the mechanism of immune tolerance in ACAID, in which antigen injected into anterior chamber is transferred exclusively through blood stream to the marginal zone in the spleen (31) . Accumulated evidence indicated that both iNKT cells (8) and marginal zone B cells (32, 33) are required for the induction of immune tolerance by the injection of protein antigen into anterior chamber.
The present experiments have shown that both an adoptive transfer of αGC-liposome-pulsed LD-B cells and an injection of αGC-liposomes could induce the development of CD11c low CD45RB
high DCs in the spleen ( Figure 3A & 3B) . Yield of splenic DCs from the αGalCer-treated mice suggested that the treatment with aqueous αGalCer increased the number of CD11c high DCs in the spleen, whereas the treatment with αGC-liposome induced the selective increase in CD11c low CD45RB
high cells (cf. table 1). These cells were similar to the tolerogenic DCs described by Wakkach et al (15) , in terms of plasmacytoid morphology, cell surface markers, low expression levels of co-stimulatory molecules, such as CD80, CD40 and I-A, and production of IL-10, rather than IL-12, upon stimulation with LPS ( Figure 3C ). In view of their findings that the CD11c low CD45RB
high tolerogenic DCs could be obtained by culture of bone marrow cells with GM-CSF in the presence of IL-10, and that the proportion of this subset in all DCs was significantly high in the spleen of IL-10 transgenic mice, one may suspect that IL-10 released from the marginal zone B cells and iNKT cells in the spleen of the αGalCer-liposome-treated mice promoted the development of the tolerogenic DCs. However, marked increase in the number of CD11c low CD45RB
high tolerogenic DCs in their spleens may not be explained by IL-10 alone. Svensson et al (34) reported that spleen-derived stroma cells promoted selective development of CD11c low CD45RB high tolerogenic DCs from progenitor cells, and that the stroma cells from the mice injected with Leishmania donovani were more effective than normal stroma cells for directing the development of the tolerogenic DCs. In the course of the present experiments for the enrichment of DCs in the spleen, we realized that the number of non-lineage cells, which include both DCs and stroma cells, markedly increased after an injection of αGalCer-liposome, and that the increase of the non-lineage cells could not be explained by the increase of CD11c low CD45RB
high tolerogenic DCs alone (cf. Table I ). One might speculate that the liposome either increase or activate the stroma cells through unknown mechanisms, such as active TGF-β1 production, and promoted the differentiation of progenitor cells towards tolerogenic DCs.
Further studies are required for elucidation of the mechanisms for the selective increase in the population of the tolerogenic DCs by an injection of αGC-liposomes. Nevertheless, the findings that transfer of αGC-liposome-pulsed LD-B cells into normal mice induced the development of tolerogenic DCs in the spleen Figure 6 . Carrier-specific suppression of the secondary antibody responses by administration of αGC-OVA-liposomes. Three groups of BDF1 mice (n=5) were immunized with alum-adsorbed DNP-OVA (0.1 µg) or alum-adsorbed DNP-KLH (1 µg) at day 0. They received intraperitoneal injections of "Liposome", "αGC-liposome" or "αGC-OVA-liposome" at day 21, 28 and 35, and then boosted with either DNP-OVA (0.1 µg) or DNP-KLH (1 µg) at day 42. The concentrations of anti-DNP IgE, IgG1 and IgG2a antibodies in their sera at day 49 were measured by ELISA. * p < 0.05, ** p < 0.005 and *** p < 0.001 for the αGC-liposome or αGC-OVA-liposome group versus liposome group. of the recipients (cf. Figure 3A) indicate that the presentation of αGalCer by marginal zone B cells to iNKT cells was responsible for the generation of CD11c low CD45RB
high DCs in the spleen.
Previous studies on the tolerogenic DCs have shown that antigen-pulsed tolerogenic DCs facilitate the development of IL-10-producing Treg (IL-10 Treg or Tr1) cells in vitro, and antigen-specific tolerance in vivo (15, 34, 35) .
The present experiments actually showed that stimulation of naïve CD4 + T cells from RAG2-deficient DO11.10 mice with antigen-pulsed CD11c + Treg (nTreg) cells, however, they expressed Foxp3 ( Figure 4A & B) , which was believed to be specifically expressed in nTreg cells (36, 37) . Expression of Foxp3 in Tr1 cells is controversial. Typical IL-10 producing Tr1 cells, which were developed by stimulating naïve DO11.10-CD4 + T cells with anti-CD3 in the presence of vitamin D3 and dexamethasone, were CD4 + CD25
+ cells, but did not express Foxp 3 (38) . However, the antigenspecific Tr1-like cells induced by neuropeptide-generated CD11c low CD45RB
high DCs expressed Foxp 3 (35) . Indeed, adoptive or inducible Treg cells developed under different experimental conditions appear to be quite heterogeneous. Previous publications indicated that both the Treg cells induced by the pulmonary dendritic cells from the mice exposed to respiratory allergen (Th2-like Treg) (39) and those induced by CD8α DCs of the mice immunized with antigen and heat-killed Listeria monocytogenis (Th1-like Treg) (7), expressed Foxp3. Indeed, the Treg cells obtained in the present experiments by the injections of αGC-OVAliposomes share common properties with the Th1-like Treg, with respect to the expression of CD25, ICOS and Foxp3, and the production of both IL-10 and IFN-γ upon stimulation with antigen-pulsed antigen presenting cells 
CD25
-cells from the majority of non-atopic donors gave proliferative response and IL-5 production upon stimulation with allergen-pulsed antigen presenting cells, and that the responses were prevented by the addition of autologous CD4 + CD25 + cells. In the active allergic pollinosis patients, however, the inhibitory effect of the autologous CD4 + CD25
+ cells was substantially less than that observed in non-atopic individuals. Subsequent studies by Akdis et al (42) identified allergen-specific Th1, Th2 and Tr1 CD4 + cells, which produce IFN-γ, IL-4 and IL-10, respectively, upon antigenic stimulation in the peripheral blood of both atopic and healthy individuals, and found that Tr1 cells are dominant subset in healthy individuals. They proposed the hypothesis that balance between allergenspecific Th2 and Tr1 cells would determine the development of healthy or allergic immune response. These findings support our expectations that αGC-liposomes containing an appropriate allergen would be a useful tool for the immunotherapy of allergic patients.
